A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)
Michael Dickinson(The University of Melbourne), Anastasios Karadimitris(NIHR Imperial Biomedical Research Centre), Aristeidis Chaidos(British Society for Haematology), Brandon E. Kremer(Providence College), Paul Yeh(The Royal Melbourne Hospital), María‐Victoria Mateos(Hospital Clínico San Carlos), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Adrían Alegre(Hospital Universitario de La Princesa), James Winnberg(GlaxoSmithKline (United States)), Lijoy K. Mathew(GlaxoSmithKline (India)), Carlos Fernández de Larrea(Hospital Clínic de Barcelona), Alejandro Martı́n(Instituto de Investigación Biomédica de Salamanca), Natalie O. Karpinich(GlaxoSmithKline (United States)), Mark A. Dawson(The University of Melbourne), Raúl Córdoba(Hospital Universitario Fundación Jiménez Díaz), Thierry Horner(GlaxoSmithKline (United States)), Arindam Dhar(GlaxoSmithKline (United States)), Jin Seok Kim(University of Ulsan), Jeffrey Botbyl(GlaxoSmithKline (United States)), Faisal Basheer, Manali Kamdar(University of Colorado Cancer Center), Won-Seog Kim(Samsung Medical Center), Paolo Gallipoli(Wellcome/MRC Cambridge Stem Cell Institute)
Cited by 15
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k